The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Dorozhenok I.Yu.

Mental Health Research Center;
Sechenov First Moscow State Medical Universit (Sechenov University)

Modern possibilities of anti-relapse therapy of schizophrenia (experience with the use of aripiprazole)

Authors:

Dorozhenok I.Yu.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(12): 63‑67

DOI: 10.17116/jnevro202212212163

Views: 3215

Downloaded: 72

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Dorozhenok IYu. Modern possibilities of anti-relapse therapy of schizophrenia (experience with the use of aripiprazole). S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(12):63‑67. (In Russ.)
https://doi.org/10.17116/jnevro202212212163

 
МСФ на ЯМ
Close metadata
Recommended articles:
Atypical anti­psychotics in the treatment of depression in affe­ctive diso­rders and schi­zophrenia (using the aripiprazole model). S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):36-42
An indi­vidual approach to the diagnosis and treatment of an acute psychotic condition in a patient with a multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):97-102

The review is devoted to the actual problem of anti-relapse therapy for schizophrenia. The features of the use, efficiency, tolerability and safety of typical and atypical antipsychotics are discussed. The possibilities of using atypical antipsychotics of the third generation — partial dopamine receptor agonists — on the aripiprazole model are considered. According to numerous studies, aripiprazole, due to its unique pharmacological profile and combination of clinical factors, is the drug of first choice for anti-relapse supportive therapy of schizophrenia.

Keywords:

anti-relapse supportive therapy for schizophrenia
atypical antipsychotics
aripiprazole
Ralotex

Authors:

Dorozhenok I.Yu.

Mental Health Research Center;
Sechenov First Moscow State Medical Universit (Sechenov University)

Received:

21.11.2022

Accepted:

30.11.2022

List of references:

  1. Schutt RK, Xie H, Mueser KT, et al. Cognitive Enhancement Therapy vs social skills training in schizophrenia: a cluster randomized comparative effectiveness evaluation. BMC Psychiatry. 2022;22(583). https://doi.org/10.1186/s12888-022-04149-x
  2. Kahn RS, Sommer IE, Murray RM, et al. Schizophrenia. Nature Reviews Disease Primers. 2015;1(1):15067. https://doi.org/10.1038/nrdp.2015.67
  3. Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet. 2016;388(10039): 86-97.  https://doi.org/10.1016/S0140-6736(15)01121-6
  4. Harvey PD. Assessing disability in schizophrenia: tools and contributors. The Journal of Clinical Psychiatry. 2014;75(10):e27.  https://doi.org/10.4088/JCP.13049tx5c
  5. Morozova MA, Burminskii DS, Rupchev GE. Variants of the dynamics of long-term drug remission in patients with onset-progressive schizophrenia (catamnesic study). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2015;115(7):22-29. (In Russ.). https://doi.org/10.17116/jnevro20151157122-29
  6. Kane JM, Correll CU. Pharmacologic treatment of schizophrenia. Dialogues Clin Neurosci. 2010;12(3):345-357.  https://doi.org/10.31887/DCNS.2010.12.3/jkane
  7. Smulevich AB. Schizophrenia at the stage of relative stabilization of the process. Problems of clinic and therapy. Sovremennaya Terapiya v Psikhiatrii i Nevrologii. 2011;(2):5. (In Russ.).
  8. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951-962.  https://doi.org/10.1016/S0140-6736(13)60733-3
  9. Orzelska-Górka J, Mikulska J, Wiszniewska A, Biała G. New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression. Int J Mol Sci. 2022;23:10624. https://doi.org/10.3390/ijms231810624
  10. Oleichik IV, Shishkovskaya TI, Baranov PA. Reasons for non-compliance with the therapy regimen of patients with mental disorders and modern ability to improve satisfaction. Sovremennaya Terapiya v Psikhiatrii i Nevrologii. 2021;(1-2):4-10. (In Russ.).
  11. Kishimoto T, Agarwal V, Kishi T, et al. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Molecular Psychiatry. 2013;18(1):53-66.  https://doi.org/10.1038/mp.2011.143
  12. Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophrenia Research. 2010;123(2-3):225-233.  https://doi.org/10.1016/j.schres.2010.07.012
  13. Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 4th Ed. New York, NY, US: Cambridge University Press; 2013.
  14. Kibitov AO, Mazo GE. Metabolic side effects of atypical antipsychotics: interpersonal variability and genetic risk. Sotsial’naya i Klinicheskaya Psikhiatriya. 2018;28(1):90-100. (In Russ.).
  15. Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs. 2004;18(4):251-267.  https://doi.org/10.2165/00023210-200418040-00005
  16. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. The Journal of Pharmacology and Experimental Therapeutics. 2002;302(1):381-389.  https://doi.org/10.1124/jpet.102.033175
  17. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. The Journal of Clinical Psychiatry. 2001;62(12):923-924.  https://doi.org/10.4088/jcp.v62n1201
  18. Topolov MK, Getova DP. Cognitive Impairment in Schizophrenia, Neurotransmitters and the New Atypical Antipsychotic Aripiprazole. Folia Medica. 2016;58(1):12-18.  https://doi.org/10.1515/folmed-2016-0002
  19. Veerman SRT, Schulte PFJ, de Haan L. Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review. Drugs. 2017;77(13):1423-1459. https://doi.org/10.1007/s40265-017-0789-y
  20. Peitl V, Štefanović M, Orlović I, et al. Long acting aripiprazole influences cognitive functions in recent onset schizophrenia. Psychopharmacology. 2021;238(6):1563-1573. https://doi.org/10.1007/s00213-021-05788-w
  21. Kern RS, Green MF, Cornblatt BA, et al. The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology. 2006;187(3):312-320.  https://doi.org/10.1007/s00213-006-0428-x
  22. DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clinical Therapeutics. 2004;26(5):649-666.  https://doi.org/10.1016/s0149-2918(04)90066-5
  23. Bhattacharjee J, El-Sayeh HGG. Aripiprazole versus typical antipsychotic drugs for schizophrenia. The Cochrane Database of Systematic Reviews. 2008;(3):CD006617. https://doi.org/10.1002/14651858.CD006617.pub3
  24. Bernagie C, Danckaerts M, Wampers M, De Hert M. Aripiprazole and Acute Extrapyramidal Symptoms in Children and Adolescents: A Meta-Analysis. CNS Drugs. 2016;30(9):807-818.  https://doi.org/10.1007/s40263-016-0367-y
  25. Casey AB, Canal CE. Classics in Chemical Neuroscience: Aripiprazole. ACS Chemical Neuroscience. 2017;8(6):1135-1146. https://doi.org/10.1021/acschemneuro.7b00087
  26. Ribeiro ELA, de Mendonça Lima T, Vieira MEB, Storpirtis S, Aguiar PM. Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews. European Journal of Clinical Pharmacology. 2018;74(10):1215-1233. https://doi.org/10.1007/s00228-018-2498-1
  27. Preda A, Shapiro BB. A safety evaluation of aripiprazole in the treatment of schizophrenia. Expert Opinion on Drug Safety. 2020;19(12):1529-1538. https://doi.org/10.1080/14740338.2020.1832990
  28. Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. The Journal of Clinical Psychiatry. 2003;64(9):1048-1056. https://doi.org/10.4088/jcp.v64n0910
  29. Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. The International Journal of Neuropsychopharmacology. 2003;6(4):325-337.  https://doi.org/10.1017/S1461145703003651
  30. Khanna P, Komossa K, Rummel-Kluge C, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. The Cochrane Database of Systematic Reviews. 2013;(2):CD006569. https://doi.org/10.1002/14651858.CD006569.pub4
  31. Ostuzzi G, Bertolini F, Tedeschi F, et al. Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants. World Psychiatry: Official Journal of the World Psychiatric Association (WPA). 2022;21(2):295-307.  https://doi.org/10.1002/wps.20972
  32. Lyubov EB. Aripiprazole (Abilify): rational choice in the treatment of schizophrenia. Sotsial’naya i Klinicheskaya Psikhiatriya. 2008;18(4):94-102. (In Russ.).
  33. Gurovich IYa, Lyubov EB, Vinidiktova GI, et al. Clinical and Social Efficacy in Supporting Treatment of Schizophrenia Aripiprazole (Abilify): Multi-faceted Evaluation. Sotsial’naya i Klinicheskaya Psikhiatriya. 2009;19(3):37-46. (In Russ.).
  34. Dorozhenok IYu. Experience with the application of the atypical antipsychotic aripiprazole (Amdoal) in psychiatric practice: clinical observations. Sovremennaya Terapiya Psikhicheskikh Rasstroistv. 2013;4:25-29. (In Russ.).
  35. Di Sciascio G, Riva MA. Aripiprazole: from pharmacological profile to clinical use. Neuropsychiatric Disease and Treatment. 2015;11:2635-2647. https://doi.org/10.2147/NDT.S88117

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.